<p>Tokyo stocks wiped out early increases and closed lower on Friday as investors cashed in on recent gains.</p>.<p>The benchmark Nikkei 225 index edged down 0.12 per cent, or 27.38 points, to 23,619.69. Over the week, however, it jumped 2.6 per cent.</p>.<p>The broader Topix index lost 0.49 per cent, or 8.09 points, to 1,647.38, but advanced 2.4 per cent from a week earlier.</p>.<p>Tokyo stocks had opened higher, extending rallies on Wall Street on revived hopes for US stimulus.</p>.<p>But shares closed in negative territory "due to profit-taking after the Nikkei showed a strong performance this week," said Shinichi Yamamoto, a broker at Okasan Securities in Tokyo.</p>.<p>"Players will continue closely watching the US presidential election while paying attention to individual shares" as Japan will soon enter its interim corporate results season, Yamamoto told AFP.</p>.<p>The dollar fetched 105.84 yen in Asian afternoon trade against 106.03 yen in New York late Thursday.</p>.<p>Japan's household spending in August was down 6.9 per cent year-on-year, against market expectations of a 6.7 per cent decline, according to data released by the internal affairs ministry before the opening bell.</p>.<p>The latest figure is the 11th consecutive monthly decline, after a 7.6 per cent decline in the previous month, with the country suffering the impact of the coronavirus pandemic.</p>.<p>In Tokyo, SoftBank lost 1.24 per cent to 6,997 yen on profit-taking, as Toyota fell 0.95 per cent to 6,967 yen with Nintendo down 0.34 per cent at 58,130 yen.</p>.<p>But Uniqlo casual wear operator Fast Retailing surged 2.86 per cent to 69,220 yen and Sony was up 0.38 per cent at 7,862 yen.</p>.<p>Takeda Pharmaceutical jumped 1.55 per cent to 3,712 yen after it announced that a Covid-19 treatment clinical trial it is involved in has entered its final Phase 3 stage with patients in the United States.</p>.<p>If successful, the project backed by the National Institute of Allergy and Infectious Diseases may eventually "become one of the earliest treatment options for hospitalised Covid-19 patients", it said.</p>
<p>Tokyo stocks wiped out early increases and closed lower on Friday as investors cashed in on recent gains.</p>.<p>The benchmark Nikkei 225 index edged down 0.12 per cent, or 27.38 points, to 23,619.69. Over the week, however, it jumped 2.6 per cent.</p>.<p>The broader Topix index lost 0.49 per cent, or 8.09 points, to 1,647.38, but advanced 2.4 per cent from a week earlier.</p>.<p>Tokyo stocks had opened higher, extending rallies on Wall Street on revived hopes for US stimulus.</p>.<p>But shares closed in negative territory "due to profit-taking after the Nikkei showed a strong performance this week," said Shinichi Yamamoto, a broker at Okasan Securities in Tokyo.</p>.<p>"Players will continue closely watching the US presidential election while paying attention to individual shares" as Japan will soon enter its interim corporate results season, Yamamoto told AFP.</p>.<p>The dollar fetched 105.84 yen in Asian afternoon trade against 106.03 yen in New York late Thursday.</p>.<p>Japan's household spending in August was down 6.9 per cent year-on-year, against market expectations of a 6.7 per cent decline, according to data released by the internal affairs ministry before the opening bell.</p>.<p>The latest figure is the 11th consecutive monthly decline, after a 7.6 per cent decline in the previous month, with the country suffering the impact of the coronavirus pandemic.</p>.<p>In Tokyo, SoftBank lost 1.24 per cent to 6,997 yen on profit-taking, as Toyota fell 0.95 per cent to 6,967 yen with Nintendo down 0.34 per cent at 58,130 yen.</p>.<p>But Uniqlo casual wear operator Fast Retailing surged 2.86 per cent to 69,220 yen and Sony was up 0.38 per cent at 7,862 yen.</p>.<p>Takeda Pharmaceutical jumped 1.55 per cent to 3,712 yen after it announced that a Covid-19 treatment clinical trial it is involved in has entered its final Phase 3 stage with patients in the United States.</p>.<p>If successful, the project backed by the National Institute of Allergy and Infectious Diseases may eventually "become one of the earliest treatment options for hospitalised Covid-19 patients", it said.</p>